Last reviewed · How we verify
Rescue Bolus
Rescue Bolus is a Small molecule drug developed by Fundación Santa Fe de Bogota. It is currently in Phase 1 development.
Rescue Bolus is a small molecule intervention used in clinical trials for various conditions, including myocardial infarction, abdominal cancer, opioid use, and bariatric surgery candidate. It has been studied in combination with primary PCI, enoxaparin, and catheterisation in clinical trials.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Rescue Bolus |
|---|---|
| Sponsor | Fundación Santa Fe de Bogota |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Muscle spasms
- Nausea
- Headache
- Grades 3-5 Cardiac Disorders
- Diarrhoea
- Dizziness
- Dyspnoea
- Hypotension
- Grades 3-5 GI Disorders
- Vomiting
- Grades 3-5 General Disorders
- Cough
Key clinical trials
- Safety and Efficacy of Dexmedetomidate vs. Midazolam for Procedural Sedation During Medical Thoracoscopy (PHASE3)
- Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma (PHASE3)
- Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) (PHASE1, PHASE2)
- Comparison of Anesthetic Techniques for Early Recovery After Ankle Arthroscopy (NA)
- Restrictive vs Liberal Intraoperative Fluid Strategy and Postoperative Outcomes After Elective Cesarean Section (NA)
- Effect of IV Lidocaine on Duodenal Peristalsis and Sedation in ERCP (PHASE4)
- Opioid-Free vs Opioid-Based Anesthesia in Bariatric Surgery (NA)
- Hemodynamics During Cesarean Delivery Under Spinal Anesthesia With Norepinephrine Versus Ephedrine (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rescue Bolus CI brief — competitive landscape report
- Rescue Bolus updates RSS · CI watch RSS
- Fundación Santa Fe de Bogota portfolio CI
Frequently asked questions about Rescue Bolus
What is Rescue Bolus?
Who makes Rescue Bolus?
What development phase is Rescue Bolus in?
What are the side effects of Rescue Bolus?
Related
- Manufacturer: Fundación Santa Fe de Bogota — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing